Evidence map›Paper›PMID 35885002›Full record

ArticleBiomedicines2022

In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells.

Victor A Naumenko, Daniil A Vishnevskiy, Aleksei A Stepanenko, Anastasiia O Sosnovtseva, Anastasiia A Chernysheva, Tatiana O Abakumova, Marat P Valikhov, Anastasiia V Lipatova, Maxim A Abakumov, Vladimir P Chekhonin

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Victor A NaumenkoV. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.
Daniil A VishnevskiyV. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.
Aleksei A StepanenkoV. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.ORCID 0000-0003-3821-6846
Anastasiia O SosnovtsevaV. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.
Anastasiia A ChernyshevaV. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.
Tatiana O AbakumovaSkolkovo Institute of Science and Technology, Bolshoy Boulevard 30, 121205 Moscow, Russia.ORCID 0000-0002-9139-3326
Marat P ValikhovV. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.
Anastasiia V LipatovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Maxim A AbakumovDepartment of Medical Nanobiotechnology, N.I Pirogov Russian National Research Medical University, 117997 Moscow, Russia.ORCID 0000-0003-2622-9201
Vladimir P ChekhoninV. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.
Federal Medical Research Centre for Psychiatry and Narcology · RUPirogov Russian National Research Medical University · RUEngelhardt Institute of Molecular Biology · RUNational University of Science and Technology · RUSkolkovo Institute of Science and Technology · RU

Funding

Russian Science Foundation 20-15-0167
6 · The paper itself

Abstract

Hepatotoxicity remains an as yet unsolved problem for adenovirus (Ad) cancer therapy. The toxic effects originate both from rapid Kupffer cell (KCs) death (early phase) and hepatocyte transduction (late phase). Several host factors and capsid components are known to contribute to hepatotoxicity, however, the complex interplay between Ad and liver cells is not fully understood. Here, by using intravital microscopy, we aimed to follow the infection and immune response in mouse liver from the first minutes up to 72 h post intravenous injection of three Ads carrying delta-24 modification (Ad5-RGD, Ad5/3, and Ad5/35). At 15-30 min following the infusion of Ad5-RGD and Ad5/3 (but not Ad5/35), the virus-bound macrophages demonstrated signs of zeiosis: the formation of long-extended protrusions and dynamic membrane blebbing with the virus release into the blood in the membrane-associated vesicles. Although real-time imaging revealed interactions between the neutrophils and virus-bound KCs within minutes after treatment, and long-term contacts of CD8+ T cells with transduced hepatocytes at 24-72 h, depletion of neutrophils and CD8+ T cells affected neither rate nor dynamics of liver infection. Ad5-RGD failed to complete replicative cycle in hepatocytes, and transduced cells remained impermeable for propidium iodide, with a small fraction undergoing spontaneous apoptosis. In Ad5-RGD-immune mice, the virus neither killed KCs nor transduced hepatocytes, while in the setting of hepatic regeneration, Ad5-RGD enhanced liver transduction. The clinical and biochemical signs of hepatotoxicity correlated well with KC death, but not hepatocyte transduction. Real-time in vivo tracking for dynamic interactions between virus and host cells provides a better understanding of mechanisms underlying Ad-related hepatotoxicity.

Indexed as

adenovirusCD8+ T cellshepatotoxicityintravital microscopyliverneutrophilszeiosis

Identifiers

PMID35885002
PMCPMC9313019
OpenAlexW4285391614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.